Zacks: Analysts Anticipate CRISPR THERAPTC (CRSP) Will Post Quarterly Sales of $2.05 Million
Wall Street analysts expect CRISPR THERAPTC (NASDAQ:CRSP) to report sales of $2.05 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for CRISPR THERAPTC’s earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $3.60 million. CRISPR THERAPTC reported sales of $1.55 million during the same quarter last year, which indicates a positive year-over-year growth rate of 32.3%. The business is expected to report its next quarterly earnings report on Tuesday, November 28th.
On average, analysts expect that CRISPR THERAPTC will report full year sales of $2.05 million for the current fiscal year, with estimates ranging from $7.30 million to $13.60 million. For the next fiscal year, analysts forecast that the business will report sales of $24.00 million per share. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover CRISPR THERAPTC.
CRISPR THERAPTC (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.06. The business had revenue of $3.60 million for the quarter, compared to the consensus estimate of $3.29 million. CRISPR THERAPTC had a negative return on equity of 47.46% and a negative net margin of 406.61%. CRISPR THERAPTC’s revenue was up 350.0% on a year-over-year basis.
Several research firms have recently issued reports on CRSP. Cann began coverage on shares of CRISPR THERAPTC in a research report on Monday, July 17th. They set a “market perform” rating for the company. Chardan Capital reaffirmed a “buy” rating on shares of CRISPR THERAPTC in a research report on Monday, August 14th. SunTrust Banks, Inc. began coverage on shares of CRISPR THERAPTC in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 price objective for the company. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of CRISPR THERAPTC in a research report on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $21.92.
CRISPR THERAPTC (CRSP) opened at 19.10 on Friday. CRISPR THERAPTC has a 12 month low of $11.63 and a 12 month high of $25.00. The firm’s market capitalization is $775.29 million. The stock’s 50 day moving average price is $18.50 and its 200-day moving average price is $17.81.
In related news, CEO Rodger Novak sold 10,825 shares of the business’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $15.37, for a total value of $166,380.25. Following the completion of the sale, the chief executive officer now directly owns 1,225,830 shares of the company’s stock, valued at $18,841,007.10. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Kurt Von Emster sold 88,011 shares of the business’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $19.79, for a total transaction of $1,741,737.69. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 827,921 shares of company stock valued at $15,063,254. Corporate insiders own 39.98% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. IHT Wealth Management LLC purchased a new stake in CRISPR THERAPTC in the first quarter valued at $110,000. Monashee Investment Management LLC lifted its position in CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after acquiring an additional 15,000 shares during the last quarter. Paulson & CO. Inc. purchased a new stake in CRISPR THERAPTC in the first quarter valued at $1,099,000. Credit Suisse AG purchased a new stake in CRISPR THERAPTC in the first quarter valued at $1,742,000. Finally, Wellington Management Group LLP lifted its position in CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after acquiring an additional 3,070 shares during the last quarter. 23.90% of the stock is owned by hedge funds and other institutional investors.
CRISPR THERAPTC Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with MarketBeat.com's FREE daily email newsletter.